Showing 621 - 640 results of 115,651 for search '(( a non decrease ) OR ( 5 ((((non decrease) OR (point decrease))) OR (a decrease)) ))', query time: 1.57s Refine Results
  1. 621
  2. 622
  3. 623
  4. 624
  5. 625
  6. 626

    Sensitivity of the optimal pathway to increased and decreased discounting (5% and 0%), to the addition of other non-cardiovascular health care costs in added years of life, the measurement of health gain in QALYs rather than DALYs, and to a reduction in the cost of statin drugs to the much lower price in New Zealand (NB. the order of interventions is altered only by the reduction in statin price, with statins becoming a more cost-effective intervention option than the blood pressure-lowering drugs). by Linda J. Cobiac (149055)

    Published 2012
    “…<p>Sensitivity of the optimal pathway to increased and decreased discounting (5% and 0%), to the addition of other non-cardiovascular health care costs in added years of life, the measurement of health gain in QALYs rather than DALYs, and to a reduction in the cost of statin drugs to the much lower price in New Zealand (NB. the order of interventions is altered only by the reduction in statin price, with statins becoming a more cost-effective intervention option than the blood pressure-lowering drugs).…”
  7. 627
  8. 628
  9. 629

    Image1_Decreased mitochondrial respiration associates with frailty in community-dwelling older adults.jpg by Gianella Liabeuf (18512634)

    Published 2024
    “…<p>Aging population has led to an increased prevalence of chronic and degenerative pathologies. A manifestation of unhealthy aging is frailty, a geriatric syndrome that implies a non-specific state of greater vulnerability. …”
  10. 630

    Reduction of SIRT1 during DNA damage decreases the number of silent clones that have methylation. by Heather M. O'Hagan (271283)

    Published 2008
    “…One representative bisulfite sequenced clone is presented for each HSVTK silent clone. (B) A dot plot of the mean number of CpGs methylated per HSVTK silenced clone from either un-siRNA treated cells (untreated) (<a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1000155#pgen-1000155-g005" target="_blank">Figure 5D & E</a>), non-target siRNA treated cells (NT), or SIRT1 siRNA treated cells (SIRT1). …”
  11. 631
  12. 632
  13. 633
  14. 634
  15. 635
  16. 636
  17. 637
  18. 638

    Belinostat decreases both male and female bladder weights in transgenic superficial bladder cancer mice by Michael T Buckley (37161)

    Published 2011
    “…All bladders were voided of urine prior to weighing. Normal non-transgenic mouse bladders weigh approximately 10.0 mg at the same age, and Ha-transgenic mice with superficial bladder cancer have a 3 fold and higher bladder weight. , Male belinostat-treated mice (n = 4, 327.5 mg average weight) showed a two-fold decrease (50%, p = 0.03) in bladder weight versus control (n = 4, 652.5 mg average weight). , Female belinostat-treated mice (n = 5, 34.0 mg average weight) showed a 36% decrease (p = 0.04) in bladder weight versus control (n = 6, 53.3 mg average weight).…”
  19. 639
  20. 640